Form D · Biotechnology
InnovoTEX Inc.
Austin, TX · CIK 0001971887
Offering snapshot reported Aug 18, 2026 · SEC filing
- Reported sold
- $75K Offering amount: $75K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 18, 2026 | Initial | $75,000 | No comparison | 2 | SEC filing |
| Aug 18, 2026 | Amendment | $2,720,484 | $1,970,533vs Aug 6, 2026 | 21 | SEC filing |
| Aug 6, 2026 | Initial | $749,951 | No comparison | 14 | SEC filing |
| Mar 31, 2023 | Initial | $829,831 | No comparison | 8 | SEC filing |
| Mar 31, 2023 | Amendment | $829,831 | $0vs Mar 31, 2023 | 8 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-594559
Source: Form D, filed Aug 18, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph Arambula | Director, Executive |
| Jonathan Arambula | Director |
| James Hussey | Director |
| Krystle Karoscik | Director, Executive |
| Krystle Karosik | Executive |
| Jonathan Sessler | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3800 North Lamar Blvd. Suite 200
Austin, TX, 78756
Phone: 570-510-6372
Austin, TX, 78756
Phone: 570-510-6372